Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region

International Journal of Environmental Research and Public Health

Jean François Durant¹  Mostafa Bentahir¹  Jean-Luc Gala¹  Bertrand Bearzatto¹  Aleksandr Vybornov¹  Nawfal Chibani¹  Jérôme Ambroise¹  Benjamin Smits¹  Omar Nyabi¹  Olivier Thellin²  BenaissaEl Moualij² 

[1] Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1348 Woluwe saint-Lambert, Belgium;Centre de Recherche sur les Protéines Prions (CRPP) ULiège, Quartier Hôpital, 15, Avenue Hippocrate, B 4000 Liège, Belgium;

关键词: SARS-CoV-2;    Public Health Preparedness;    emerging biological threats;   

DOI  :  10.3390/ijerph18073372

来源: DOAJ

【 摘 要 】

Coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by the novel coronavirus (SARS-CoV-2) identified in 2019. The COVID-19 outbreak continues to have devastating consequences for human lives and the global economy. The B-LiFe mobile laboratory in Piedmont, Italy, was deployed for the surveillance of COVID-19 cases by large-scale testing of first responders. The objective was to assess the seroconversion among the regional civil protection (CP), police, health care professionals, and volunteers. The secondary objective was to detect asymptomatic individuals within this cohort in the light of age, sex, and residence. In this paper, we report the results of serological testing performed by the B-LiFe mobile laboratory deployed from June 10 to July 23, 2020. The tests included whole blood finger-prick and serum sampling for detection of SARS-CoV-2 spike receptor-binding domain (S-RBD) antibodies. The prevalence of SARS-CoV-2 antibodies was approximately 5% (294/6013). The results of the finger-prick tests and serum sample analyses showed moderate agreement (kappa = 0.77). Furthermore, the detection rates of serum antibodies to the SARS-CoV-2 nucleocapsid protein (NP) and S-RBD among the seroconverted individuals were positively correlated (kappa = 0.60), at least at the IgG level. Seroprevalence studies based on serological testing for the S-RBD protein or SARS-CoV-2 NP antibodies are not sufficient for diagnosis but might help in screening the population to be vaccinated and in determining the duration of seroconversion.

【 授权许可】

Unknown